Secondary endpoints
in response to
by
posted on
Oct 22, 2019 06:32PM
I’ve been reminding myself of the secondary endpoints. Two that interest me will be CVD mortality and total mortality. It’s not impossible that a drug like apabetalone with multiple potentially beneficial metabolic effects in diabetics could lower one or the other mortalities without reducing the primary endpoint. That would a big one. Do we know what the total number of deaths was in the combined groups?